Should ICSI be used in non-male factor infertility?
There is general agreement that intracytoplasmic sperm injection (ICSI) should be used in male factor infertility cases, such as oligoasthenoteratozoospermia, presence of anti-sperm antibodies, or azoospermia, these cases being diagnosed through abnormal semen analysis. There are no randomized clinical trials comparing ICSI with IVF (or other interventions) where semen quality is so poor that IVF would not achieve fertilization. It is accepted that ICSI is the only treatment option in those circumstances. The role of ICSI where IVF can be expected to give a reasonable fertilization rate is the question that needs to be answered. The argument is whether or not ICSI should be used for all cases of infertility. This paper proposes and strongly supports the use of ICSI for all indications. Considerations of fertilization and embryo development, cost effectiveness and safety will be clearly discussed.
Orief
Yasser
Y
Department of Obstetrics and Gynecology, Shatby University Hospital, Alexandria University, Egypt.
Dafopoulos
Konstantinos
K
Al-Hassani
Safaa
S
D002869:Chromosome Aberrations; D005306:Fertilization / Q000502:physiology*; D005307:Fertilization in Vitro / Q000191:economics / Q000379:methods; D030342:Genetic Diseases, Inborn / Q000453:epidemiology; D006801:Humans; D007248:Infertility, Male / Q000628:therapy*; D008297:Male; D012661:Semen / Q000737:chemistry*; D020554:Sperm Injections, Intracytoplasmic / Q000191:economics / Q000379:methods*